Magenta Therapeutics Inc Share Price Today: Live Updates & Key Insights

Magenta Therapeutics Inc share price today is $79.1, up -2.8%. The stock opened at $79.815 against the previous close of $80, with an intraday high of $81.24 and low of $75.8.

Magenta Therapeutics Inc Share Price Chart

Magenta Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Magenta Therapeutics Inc Share Price Performance

$79.1 -0.028(-2.8%) DNTH at 23 Mar 2026 12:44 PM Biotechnology
Lowest Today 75.8
Highest Today 81.24
Today’s Open 79.815
Prev. Close 80
52 Week High 88.02
52 Week Low 13.37
Day’s Range: Low 75.8 High 81.24
52-Week Range: Low 13.37 High 88.02
1 day return -
1 Week return -0.07
1 month return +47.83
3 month return +77.54
6 month return +105.76
1 year return +301.13
3 year return +539.88
5 year return -63.7
10 year return -

Magenta Therapeutics Inc Institutional Holdings

Magenta Therapeutics Inc Market Status

Strong Buy: 10

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Magenta Therapeutics Inc Fundamentals

Market Cap 3361.03 M

PB Ratio 6.3207

PE Ratio 0.0

Enterprise Value 3056.52 M

Total Assets 530.92 M

Volume 2415391

Magenta Therapeutics Inc Company Financials

Annual Revenue FY23:3544000 3.5M, FY22:6417000 6.4M, FY21:1476000 1.5M, FY20:null 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:6417000 6.4M, FY21:1476000 1.5M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-43108000 -43.1M, FY22:-28476000 -28.5M, FY21:-13109000 -13.1M, FY20:-74936000 -74.9M, FY19:-76769000 -76.8M

Quarterly Revenue Q3/2025:396000 0.4M, Q2/2025:193000 0.2M, Q1/2025:1163000 1.2M, Q3/2024:2172000 2.2M, Q2/2024:1863000 1.9M

Quarterly Profit Q3/2025:396000 0.4M, Q2/2025:193000 0.2M, Q1/2025:1163000 1.2M, Q3/2024:2172000 2.2M, Q2/2024:1752000 1.8M

Quarterly Net worth Q3/2025:-36765000 -36.8M, Q2/2025:-31629000 -31.6M, Q1/2025:-29511000 -29.5M, Q3/2024:-25174000 -25.2M, Q2/2024:-17607000 -17.6M

About Magenta Therapeutics Inc & investment objective

Company Information Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Organisation Biotechnology

Employees 92

Industry Biotechnology

CEO Mr. Marino Garcia M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Magenta Therapeutics Inc FAQs

What is the share price of Magenta Therapeutics Inc today?

The current share price of Magenta Therapeutics Inc is $79.1.

Can I buy Magenta Therapeutics Inc shares in India?

Yes, Indian investors can buy Magenta Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Magenta Therapeutics Inc shares in India?

You can easily invest in Magenta Therapeutics Inc shares from India by:

Can I buy fractional shares of Magenta Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Magenta Therapeutics Inc?

Magenta Therapeutics Inc has a market cap of $3361.03 M.

In which sector does Magenta Therapeutics Inc belong?

Magenta Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Magenta Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Magenta Therapeutics Inc?

The PE ratio of Magenta Therapeutics Inc is N/A and the PB ratio is 6.32.